Investigational drug · Phase 3
NTQ5082
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Paroxysmal Nocturnal Hemoglobinuria, Primary IgA Nephropathy.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
7
Any phase or sponsor naming "NTQ5082"
First trial start
2025
Jan 23, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NTQ5082", any sponsor or status.
Conditions studied
As listed on its trial records.
- Paroxysmal Nocturnal Hemoglobinuria
- Primary IgA Nephropathy
Approved drugs for the same conditions: Paroxysmal nocturnal hemoglobinuria · IgA nephropathy · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "NTQ5082" as an intervention, largest first.
Nanjing Chia-tai Tianqing PharmaceuticalIndustry
NCT06560593 · 82 participants (planned) · Start Aug 2024 · Primary completion Dec 2024
Drug: NTQ5082; Placebo · For: Complement-mediated Hemolytic Diseases
Sites: Changsha, China
- Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA NephropathyNot yet recruiting
Nanjing Chia-tai Tianqing PharmaceuticalIndustry
NCT06982040 · 80 participants (planned) · Start May 2025 · Primary completion Sep 2026
Drug: NTQ5082 capsules 100 mg; NTQ5082 capsules 200 mg and 2 more · For: Primary IgA Nephropathy
- A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria PatientsPivotal-lookingNot yet recruiting
Nanjing Chia-tai Tianqing PharmaceuticalIndustry
NCT07177859 · 78 participants (planned) · Start Nov 2025 · Primary completion Nov 2026
Drug: NTQ5082 capsules 200 mg; Eculizumab Injection · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Tianjin, China
- A Long-term Efficacy and Safety of NTQ5082 CapsulesPivotal-lookingNot yet recruiting
Nanjing Chia-tai Tianqing PharmaceuticalIndustry
NCT07177872 · 78 participants (planned) · Start Jun 2026 · Primary completion Jun 2028
Drug: NTQ5082 capsules 200 mg · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Tianjin, China
- A Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria PatientsActive, not recruiting
Nanjing Chia-tai Tianqing PharmaceuticalIndustry
NCT06764303 · 24 participants (planned) · Start Jan 23, 2025 · Primary completion Jul 8, 2025
Drug: NTQ5082 100mg qd; NTQ5082 200mg qd · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Tianjin, China; Hangzhou, China
The Third Xiangya Hospital of Central South UniversityAcademic, hospital or other
NCT07745439 · 18 participants (planned) · Start Jul 30, 2026 · Primary completion Jul 30, 2026
Drug: NTQ5082; Midazolam · For: Healthy Volunteers; Drug-Drug Interaction (DDI)
- Effect of Food of NTQ5082 in Healthy SubjectsStatus unknown
Nanjing Chia-tai Tianqing PharmaceuticalIndustry
NCT06558656 · 12 participants (planned) · Start Aug 2024 · Primary completion Dec 2024
Drug: NTQ5082 capsule · For: Complement-mediated Hemolytic Diseases
Sites: Changsha, China
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and Safety of NTQ5082 in Complement Inhibitor-Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria.
Zhang L, Xu G, Xia L, et al. · Am J Hematol 2026
Also in development for Paroxysmal Nocturnal Hemoglobinuria
- HRS-5965Phase 36 trials
Chengdu Suncadia Medicine Co., Ltd. · Primary IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria
- CemdisiranALN-CC5Phase 35 trials
Regeneron · Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, Age-related Macular Degeneration (AMD)
- HSK39297Phase 35 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Haemoglobinuria (PNH)
- MY008211APhase 35 trials
Wuhan Createrna Science and Technology Co., Ltd · Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN)
- FXS6837Phase 34 trials
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Paroxysmal Nocturnal Hemoglobinuria, Primary IgAN, IgAN
- NM8074Phase 28 trials
NovelMed Therapeutics · Paroxysmal Nocturnal Hemoglobinuria, Dermatomyositis, PNH - Paroxysmal Nocturnal Hemoglobinuria
- LP-005Phase 24 trials
Longbio Pharma · Periodontitis, Paroxysmal Nocturnal Hemoglobinuria, Complement-mediated Renal Diseases
- HS-10542Phase 22 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · IgAN, Immunoglobulin A Nephropathy (IgAN), Glomerular Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.